Share this comment
Rate per 100k may be the best metric that we have but a very flawed metric. As someone gives as an example: in a population of 10 (7 vaxxed/ 3 unvaxxed) with 3 vaxxed and 3 unvaxxed cases, the rates would be 42% & 100% which would lead you to believe significant protection for the vaxxed component. The smaller the unvaxxed group is (and …
Rate per 100k may be the best metric that we have but a very flawed metric. As someone gives as an example: in a population of 10 (7 vaxxed/ 3 unvaxxed) with 3 vaxxed and 3 unvaxxed cases, the rates would be 42% & 100% which would lead you to believe significant protection for the vaxxed component. The smaller the unvaxxed group is (and it is shrinking), the less relevant the rates per 100k are and the more relevant actual case numbers begin to be.- JMO
The original Phase 3 tests (Pfizer? Moderna? Both?) even though each arm (vaccine, placebo) had about 20,000 people each, the claimed success rates for efficacy were based on not much larger numbers! Talk about making grandiose extrapolations from tiny samples!.